SCHEMBL12813376

SCHEMBL12813376

Cc1cnc(Nc2ccc(CN3CCN(C)CC3)cc2)nc1-c1ccc(F)c(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 15/20 1.00
▸ MERTK Q12866 3/20 0.56
▸ MET P08581 2/20 0.56
▸ CDK1 P06493 1/20 0.51
▸ KDR P35968 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12964740 0.87 AXL (1.00) AXLMERTKMETCDK1KDR
SCHEMBL12813489 0.87 AXL (0.77) AXLMERTKCDK1KDR
SCHEMBL12964729 0.87 AXL (1.00) AXLMERTKMET
SCHEMBL12964809 0.86 AXL (1.00) AXL
SCHEMBL13584482 0.84 AXL (0.73) AXLMERTKMET
SCHEMBL12964813 0.83 AXL (0.73) AXLCDK1KDR
SCHEMBL12964737 0.83 AXL (1.00) AXLMERTKMET
SCHEMBL12964726 0.82 AXL (0.70) AXLCDK1KDR
SCHEMBL21317668 0.82 AXL (0.81) AXLCDK1KDR
SCHEMBL12964739 0.81 AXL (0.80) AXLCDK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165857-A1 AXL KINASE INHIBITORS AND USE OF THE SAME SUMITOMO PHARMA ONCOLOGY, INC. 2023-06-01 — — US disclosed
US-20230165857-A1 AXL KINASE INHIBITORS AND USE OF THE SAME SUMITOMO PHARMA ONCOLOGY, INC. 2023-06-01 — — US disclosed
US-20210205304-A1 AXL KINASE INHIBITORS AND USE OF THE SAME SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-07-08 — — US disclosed
US-11013741-B1 AXL kinase inhibitors and use of the same SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) 2021-05-25 — — US disclosed
US-10888562-B1 — — 2021-01-12 — — US disclosed
EP-3628665-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE University of Utah Research Foundation (US) 2020-04-01 — — EP disclosed
WO-2019195753-A1 AXL KINASE INHIBITORS AND USE OF THE SAME TOLERO PHARMACEUTICALS, INC. (US) 2019-10-10 — — WO disclosed
EP-2693881-B1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE UNIV UTAH RES FOUND (US) 2019-09-04 — — EP disclosed
EP-2693881-B1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE UNIV UTAH RES FOUND (US) 2019-09-04 — — EP disclosed
US-8901120-B2 Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-12-02 — — US disclosed
US-8901120-B2 Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-12-02 — — US disclosed
US-8901120-B2 Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-12-02 — — US disclosed
EP-2693881-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE University of Utah Research Foundation (US) 2014-02-12 — — EP disclosed
US-20120283261-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE SUMITOMO PHARMA ONCOLOGY, INC. 2012-11-08 — — US disclosed
US-20120283261-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE SUMITOMO PHARMA ONCOLOGY, INC. 2012-11-08 — — US disclosed
US-20120283261-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE SUMITOMO PHARMA ONCOLOGY, INC. 2012-11-08 — — US disclosed
WO-2012135800-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-10-04 — — WO disclosed
WO-2012135800-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283261-A1 SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE AXL, TYRO3, MERTK AXL 1/4885MERTK 3/4885MET 317/4885
US-11013741-B1 AXL kinase inhibitors and use of the same AXL, FLT3, TEC AXL 1/4885MERTK 5/4885MET 126/4885
US-20210205304-A1 AXL KINASE INHIBITORS AND USE OF THE SAME AXL, FLT3, TEC AXL 1/4885MERTK 8/4885MET 117/4885
US-20230165857-A1 AXL KINASE INHIBITORS AND USE OF THE SAME AXL, FLT3, TEC AXL 1/4885MERTK 6/4885MET 134/4885
US-10888562-B1 — TP53, TARBP2, FLT3 AXL 927/4885MERTK 1589/4885MET 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback